• Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism 

  Beauchamp, LC; Villemagne, VL; Finkelstein, D; Dore, V; Bush, A; Barnham, KJ; Rowe, CC (NATURE RESEARCH, 2020-10-23)

  Motor deficits in parkinsonism are caused by degeneration of dopaminergic nigral neurons. The success of disease-modifying therapies relies on early detection of the underlying pathological process, leading to early ...

• Exploring the Use of Helicogenic Amino Acids for Optimising Single Chain Relaxin-3 Peptide Agonists 

  Lee, HS; Wang, SH; Daniel, JT; Hossain, MA; Clark, RJ; Bathgate, RAD; Rosengren, KJ (MDPI, 2020-10-01)

  Relaxin-3 is a highly conserved two-chain neuropeptide that acts through its endogenous receptor the Relaxin Family Peptide-3 (RXFP3) receptor. The ligand/receptor system is known to modulate several physiological processes, ...

• Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer's disease therapy 

  Zhou, Y; Zhu, F; Liu, Y; Zheng, M; Wang, Y; Zhang, D; Anraku, Y; Zou, Y; Li, J; Wu, H; ... (AMER ASSOC ADVANCEMENT SCIENCE, 2020-10-01)

  Toxic aggregated amyloid-β accumulation is a key pathogenic event in Alzheimer's disease (AD), which derives from amyloid precursor protein (APP) through sequential cleavage by BACE1 (β-site APP cleavage enzyme 1) and ...

View more